David Bouchey

Dr. David Bouchey is a Managing Director & Head of Healthcare Equity Research at Aegis Capital Corp.
Dr. Bouchey worked as a healthcare analyst at C.E.
Unterberg, Towbin, LLC, Canaccord Adams Inc. and RBC Capital Markets Corp.
focusing on small and mid-cap companies.
Dr. Bouchey spent 16 years as a research scientist at different University labs before becoming a sell-side analyst, where he spent 20 years identifying and evaluating emerging biotechnology and medical device companies.
During his career, Dr. Bouchey analyzed hundreds of companies and over a hundred clinical trials, FDA applications and product launches.
Dr. Bouchey was recognized for his research analysis by Institutional Investor Magazine, which designated him a Double Home Run Hitter, the only analyst to achieve that status since 1995.
Dr. Bouchey also spent 8 years as an industry consultant and executive at Pharmacyclics and Capital Genomics, as well as the CEO of AntiSomaGen, a start-up biotechnology company.
Dr. Bouchey holds a PhD in cell and molecular biology from the University of Virginia, an MBA in finance and monetary economics from the University of Kentucky, an MS in Virology from the University of Kentucky and a BS in Microbiology and Public Health from Michigan State University.
He holds FINRA Series 7, 86 and 87 licenses.